Lisata Therapeutics (LSTA) AI Stock Analysis

• Market Cap: $22.42M
• Dividend Yield: N/A
• Average Volume (3M): 52.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: N/A
• EPS Growth: 12.95%
• Country: US
• Employees: 26
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -0.54
• Shares Outstanding: 8,755,948
• 10 Day Avg. Volume: 45,566
• 30 Day Avg. Volume: 52,287
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.12
• Enterprise Value/Revenue: 2.59
• Enterprise Value/Gross Profit: 2.94
• Enterprise Value/Ebitda: -0.14
• 1Y Price Target: $23.50
• Price Target Upside: 828.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 43 Neutral
• Price Target: ―

Lisata Therapeutics is navigating through financial difficulties with persistent losses and negative cash flows. The stock's technical indicators and valuation reflect a challenging financial position. However, recent advancements in clinical trials and regulatory achievements offer potential upside, albeit with high risk.

Positive Factors

Clinical Trial Results

The ASCEND Phase 2b trial in metastatic pancreatic ductal adenocarcinoma shows promising results with a high progression-free survival rate in the certepetide group.

Strategic Collaboration

The expanded collaboration with GATC Health is set to de-risk and accelerate drug development, enhancing potential success rates.

Negative Factors

Drug Development Challenges

The need to optimize Phase 3 development of certepetide in mPDAC highlights potential challenges in achieving successful outcomes.

Regulatory and Development Risks

Entering Phase 1 human trials for GATC's OUD asset underscores potential regulatory hurdles and development risks.

Lisata Therapeutics Business Overview & Revenue Model

Company Description

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

How the Company Makes Money

Lisata Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company may earn money via partnerships with larger pharmaceutical companies, licensing agreements, and potential sales of its approved therapies. Additionally, Lisata could receive milestone payments and royalties based on the successful development and commercialization of its products. However, as a clinical-stage company, Lisata's revenue generation is typically dependent on the progression of its drug candidates through clinical trials and eventual regulatory approvals.

Lisata Therapeutics Financial Statement Overview

Summary

Lisata Therapeutics faces significant financial challenges with ongoing losses and negative cash flows. Despite a strong equity position and no debt, the lack of revenue consistency and high operational costs are critical concerns.

Income Statement

Lisata Therapeutics has faced significant challenges with revenue and profitability. The company reported a substantial net loss of $19,985,000 in the most recent year, despite a modest revenue of $1,000,000. Gross profit margin is quite high at 100% due to minimal cost of goods sold, but this is overshadowed by negative EBIT and EBITDA margins, indicating operational inefficiencies. The revenue growth rate is not applicable, given the absence of revenue in the prior year, which highlights volatility in revenue generation.

Balance Sheet

The company's balance sheet shows moderate strength with a high equity ratio of 84.5%, and zero total debt suggesting financial prudence in leveraging. However, the return on equity is negative due to ongoing losses, which is a concern. Cash reserves have declined over the years, reflecting the company's cash burn rate amid its losses.

Cash Flow

The cash flow statement reveals a negative free cash flow of $19,356,000, indicating the company is not generating enough cash to cover its expenditures. The operating cash flow to net income ratio is positive, yet the absolute cash flow figures remain negative. The absence of capital expenditures suggests limited investment in growth initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.07M	1.00M	0.00	121.37M	0.00	0.00
Gross Profit	942.00K	1.00M	-189.00K	63.77M	-55.00K	-63.00K
EBITDA	-20.12M	-22.23M	-25.52M	-56.63M	-29.00M	-19.08M
Net Income	-18.92M	-19.98M	-20.84M	-54.23M	-27.47M	-8.15M
Balance Sheet
Total Assets	25.16M	35.00M	54.69M	73.03M	97.01M	36.00M
Cash, Cash Equivalents and Short-Term Investments	21.97M	31.25M	50.53M	69.23M	94.97M	34.57M
Total Debt	47.00K	137.00K	305.00K	485.00K	714.00K	624.00K
Total Liabilities	4.38M	5.68M	6.80M	6.71M	5.01M	3.76M
Stockholders Equity	21.03M	29.57M	48.15M	66.58M	92.25M	32.50M
Cash Flow
Free Cash Flow	-16.40M	-19.36M	-20.03M	-21.45M	-22.30M	-8.84M
Operating Cash Flow	-16.40M	-19.36M	-20.03M	-21.17M	-22.25M	-8.82M
Investing Cash Flow	5.02M	13.23M	10.10M	28.91M	-54.90M	-7.28M
Financing Cash Flow	-55.00K	-206.00K	385.00K	-224.00K	85.28M	18.58M

Lisata Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.53
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSTA, the sentiment is Negative. The current price of 2.53 is below the 20-day moving average (MA) of 2.65, below the 50-day MA of 2.63, and below the 200-day MA of 2.63, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.71 is Neutral, neither overbought nor oversold. The STOCH value of 19.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LSTA.

Lisata Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IPA	63 Neutral	$93.23M	―	-102.69%	―	-3.20%	12.24%
Sector *	57 Neutral	£5.18B	4.90	-44.55%	2.33%	28.89%	-10.08%
LSTA	43 Neutral	$22.42M	―	-63.84%	―	―	12.95%
PMN	38 Underperform	$20.59M	―	-19.56%	―	―	71.47%
BCAB	35 Underperform	$21.38M	―	-813.88%	―	―	49.48%
ELEV	33 Underperform	$21.62M	―	-78.32%	―	―	47.73%
JUNS	―	$44.36M	―		―	―	―

Lisata Therapeutics Corporate Events

Lisata Therapeutics Reports 2024 Financial Results and Updates

On February 27, 2025, Lisata Therapeutics reported its financial results for the fiscal year ending December 31, 2024, and provided a business update. The company highlighted promising preliminary data from its Phase 2b ASCEND trial for pancreatic cancer and announced the completion of enrollment in Qilu’s Phase 2 trial for certepetide. Lisata is advancing its development portfolio with multiple milestones expected over the next year, supported by a cash runway extending into the second quarter of 2026. The company is conducting several clinical trials globally, focusing on the efficacy of certepetide in combination with standard-of-care treatments for various cancers, including pancreatic, cholangiocarcinoma, and glioblastoma.